Últimas noticias sobre Genenta Science (NASDAQ:GNTA) Bolsa

Genenta Science

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.

Genenta Science S.p.A. - American Depositary Shares

Genenta Science SPA

Election polls continue to show a close race between Donald Trump and Vice President Kamala Harris in key swing states with less than one month to go until the<a href="https://www.benzinga.com/topic/2024-election"> 2024 presidential election.</a>
What Happened: While Harris posted a lead in <a href="https://www.benzinga.com/general/politics/24/10/41241771/harris-vs-trump-vice-president-hits-record-lead-in-2024-election-poll-but-independent-voters-cou">most 2024 election polls</a> of national voters, swing state polls have been much closer.
A new Emerson College <a href="https://emersoncollegepolling.com/october-2024-state-polls-mixed-movement-across-swing-states-shows-dead-heat/">poll </a>of voters in seven key swing states shows a close race between the two candidates with Trump having the edge.
Here are the results, and the totals from <a href="https://www.benzinga.com/general/politics/24/09/40949853/harris-in-trouble-new-swing-state-poll-shows-trump-gains-ground-in-key-battleground-areas-for-20">the previous poll</a> in parentheses:
<ul>
<li>Arizona: Trump 49% (49%), Harris 47% (48%)</li>
<li>Georgia: Trump 49% (50%), Harris 48% (47%)</li>
<li>Michigan: Trump 49% (47%), Harris 49% (49%)</li>
<li>Nevada: Harris 48% (48%), Trump 47% (48%)</li>
<li>North Carolina: Trump 49% (48%), Harris 48% (49%)</li>
<li>Pennsylvania: Trump 49% (48%), Harris 48% (47%)</li>
<li>Wisconsin: Trump 49% (49%), Harris 49% (48%)</li>
</ul>
The polls show Trump leading in four of the seven states, Harris leading in one state and the two candidates tied in two states. The last Emerson College poll of the seven states had Trump leading in four states with Harris leading in two states. The August poll had each candidate leading three states.
In the latest poll, Trump gained support in three states, lost support in two states and saw the same support in two states. Harris gained support in three states, lost support in two states and saw the same support in two states.
"With just under four weeks to go, the race remains too close to call in key swing states, all within the margin of error," Emerson College Polling executive director Spencer Kimball said.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent101024">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: The <a href="https://www.benzinga.com/topic/swing-states">seven swing states</a> in question together represent 93 electoral votes in the 2024 election. Six of the seven states above were won by Biden in the 2020 election with Trump winning North Carolina. Several of the states were flipped from Trump's win in the 2016 election.
Harris has seen the number of swing states she led in or tied with Trump in decline in recent months, which could be bad news for the vice president.
With swing states playing a pivotal role in who wins the election, Harris will need to see support build in the election homestretch for election forecasters to give her a good chance to win the election.
Election polls aren't perfect and the fact the poll results are within its margin of error points to an incredibly close election too close to call.
Read Next: <a href="https://www.benzinga.com/general/entertainment/24/10/41282077/trump-rejects-debate-offers-from-fox-cnn-as-harris-agrees-to-town-hall-there-will-be-no-rem"> • Trump Rejects Debate Offers From Fox, CNN As Harris Agrees To Town Hall: &#8216;There Will Be No Rematch&#8217;</a>
Photo: Shutterstock

Politics

Trump Vs. Harris: 2024 Election Swing State Poll 'Too Close To Call,' But This Candidate Leads

Artificial intelligence (AI) stocks are surging and the 2024 presidential election is shaping up to be one of the most contentious in history. But ask retail traders how it affects them and <a href="https://www.benzinga.com/topic/retail-traders">the response is, &#8220;meh.</a>&#8220;
What Happened: According to the latest survey from Public, an investing platform that prides itself on helping members build asset portfolios, most retail traders just aren&#8217;t <a href="https://www.benzinga.com/money/best-artificial-intelligence-stocks">excited by AI stocks</a>.
Never mind the fact that AI companies — Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) — saw significant gains and outpaced broader market <a href="https://www.benzinga.com/top-stories/24/06/39383798/the-ai-big-10-10-ai-stocks-now-comprise-28-of-s-p-500-up-from-14-in-2023">indexes like the S&amp;P 500</a>.
Of the 1,300 responses Public <a href="https://public.com/research/2024-retail-investor-report">sourced</a> from investors, the firm determined:
<ul>
<li>35% say that new technology excites them.</li>
<li>30% have purchased a company stock because of their AI capabilities.</li>
<li>64% say AI will be a standard tool for research in the future.</li>
<li>50% are likely to use it to process financial information in the future.</li>
</ul>
The contentious presidential election between Republican Donald Trump and Democrat Vice President Kamala Harris doesn&#8217;t seem to faze investors, either.
&#8220;Many investors are indifferent to the election as it relates to the market or their own portfolio, but a number of investors purchased company stocks or traded options based on who they predict will win and how it will benefit their portfolio,&#8221; Public derived from the findings. 
Here&#8217;s a breakdown:
<ul>
<li>63% say no, the election does not impact their investing strategy.</li>
<li>37% say yes, it does impact their investing strategy.</li>
<li>16% of investors are buying more stocks or options of a company based on who they predict will win and the impact it will have on their portfolio.</li>
<li>13% are investing less in 2024 due to the election.</li>
<li>12% are investing more.</li>
</ul>
There is also a direct 50/50 split among investors saying that economic data from the Federal Reserve impacts their investing decisions with 50.4% of retail traders saying &#8220;yes&#8221; and 49.6% saying &#8220;no.&#8221;
See Also: <a href="https://www.benzinga.com/general/politics/24/10/41279272/donald-trump-pushes-tariffs-on-chinese-cars-in-detroit-visit-vows-to-revamp-industry">Trump Pushes Tariffs On Chinese Cars In Detroit Visit, Vows To Revamp Industry</a>
Why It Matters: The ho-hum response toward the economy is <a href="https://www.benzinga.com/news/24/09/41049170/harris-vs-trump-55-cfos-believe-vice-president-likely-to-win-election-although-ex-president-is-bette">something that has plagued</a> the Biden-Harris administration for months, despite solid numbers.
As <a href="https://www.benzinga.com/topic/election-day">Election Day draws near</a>, there is ongoing coverage of how the electorate views the economy and costs.
But here are the facts:
<ul>
<li>Annual inflation has <a href="https://www.benzinga.com/markets/equities/24/10/41272627/dow-falls-over-100-points-us-inflation-rate-slows-to-2-4-in-september">fallen to 2.4 percent</a>, its slowest pace since early 2021.</li>
<li>The <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41184080/us-economy-adds-254-000-new-jobs-in-september-smashes-expectations-unemployment-f">unemployment rate recently dropped</a> to 4.1%</li>
<li>With gains of 20.9%, the S&amp;P 500 year-to-date performance is up from <a href="https://www.benzinga.com/general/education/24/10/41191050/s-p-500-to-end-year-over-6-000-34-of-benzinga-readers-predict-raging-bull-run">recent presidential election years</a>.</li>
<li>Consumer morale hit <a href="https://www.benzinga.com/24/09/40857449/consumer-morale-hits-4-month-high-inflation-expectations-ease-partisan-gaps-in-sentiment-inched-up">a four-month high</a> in September, driven by more spending and <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40812986/inflation-slows-to-2-5-in-august-lowest-rate-since-february-2021-core-index-remai">favorable price conditions</a>.</li>
</ul>
And regarding AI, automation continues to be a <a href="https://www.wsj.com/business/logistics/us-ports-automation-union-strike-f94bb4b7">major point of concern</a> to labor workers who fear replacement. In June, the Kobeissi Letter claimed the AI hype was &#8220;<a href="https://twitter.com/KobeissiLetter/status/1802793751120592960">stronger than ever</a>.&#8221; 
As for what retail traders care about when crafting their portfolios, Public ranked these responses: strong earnings, personal confidence in a company, leadership, transparent communication and familiarity with the brand. See chart below.
<figure class="wp-block-image size-large"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10165546/Screenshot-2024-10-10-at-4.53.57%E2%80%AFPM-1024x657.png" alt="With more data available today than ever before, investors pay attention 
to more than just financials before making an investment decision. Here 
is a breakdown of what is important to them ranked in order of 
importance before investing in a company: 
Strong earnings 
Personal confidence in a company 
Strong leadership 
Transparent communication 
Familiarity with the brand" class="wp-image-590277"/><figcaption class="wp-element-caption">Courtesy of Public.com</figcaption></figure>
Now Read:
<ul>
<li><a href="https://www.benzinga.com/real-estate/24/10/41272556/renters-say-kamala-harris-beats-trump-on-housing-affordability-48-choose-the-vice-president">Kamala Harris Beats Trump On Housing Affordability, Renters Say </a></li>
</ul>
Photo: Shutterstock

Federal Reserve

NVDA

SMCI

Retail Traders Unfazed By AI Hype, Most Say 2024 Election Is As Relevant To Portfolios As A Magic 8-Ball

As California's cannabis market expanded after legalization, several leading companies seemed poised for dominance. However, due to mismanagement, regulatory pressures and market saturation, many of these giants have collapsed. Here's a closer look at the industry's most notable failures.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h3 class="wp-block-heading">MedMen: From Unicorn To Bankruptcy</h3>
MedMen, once celebrated as the &#8220;Apple Store of Weed,&#8221; reached a $2 billion valuation. However, rapid expansion, failed acquisitions, and leadership turnover created financial turmoil. By April 2024, MedMen had filed for bankruptcy with $411 million in liabilities.
<h3 class="wp-block-heading">Eaze: The Uber Of Weed Falls</h3>
Eaze, once California's largest cannabis delivery service, <a href="https://www.benzinga.com/markets/cannabis/24/04/38282181/eaze-delivery-workers-threaten-first-cannabis-strike-of-2024-amid-ongoing-negotiations">defaulted </a>on a $36.9 million loan and was later acquired by billionaire James Henry Clark. Despite the change in ownership, Eaze could not recover from high operating costs, regulatory burdens and competition from unlicensed operators. 
The company will shut down by December 2024, leaving 500 employees without jobs. This failure underscores the harsh market conditions many cannabis businesses face.
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/09/41053140/i-dealt-with-gangsters-shakedowns-loan-sharks-and-government-corruption-says-entrepreneur-who-bu"> &#8216;I Dealt With Gangsters, Shakedowns, Loan Sharks And Government Corruption,&#8217; Says Entrepreneur Who Built The First Cannabis Unicorn</a>
<h3 class="wp-block-heading">FlowKana: Bye Bye To The Sustainable Dream</h3>
FlowKana was a pioneer in promoting sustainability and small farmers, but it struggled with <a href="https://www.benzinga.com/topic/california-cannabis">California&#8217;s regulatory environment </a>and a market flooded with excess supply. Despite raising $175 million and becoming California's top-selling flower brand in 2018, the company couldn't survive the dramatic drop in wholesale cannabis prices.&nbsp;
FlowKana paid as low as $350 per pound for lower-grade flowers in 2019, far below sustainable levels. The company ceased operations in 2023, reflecting the challenges of balancing sustainability with profitability in a turbulent market.
<h3 class="wp-block-heading">Herbl: The Supply Chain Giant Stumbles</h3>
Herbl, once a major force in <a href="https://www.benzinga.com/topic/california-cannabis">California's cannabis distribution network</a>, handled approximately $700 million in annual sales and worked with over 1,000 licensed retailers. However, the company's collapse in 2024 was marked by severe liquidity problems and an inability to keep up with mounting unpaid invoices.&nbsp;
Facing a canceled line of credit from its primary lender, East West Bank, Herbl&#8217;s financial health rapidly <a href="https://mjbizdaily.com/big-california-marijuana-distributor-herbl-collapses-brands-left-unpaid/">deteriorated</a>, leading to millions of dollars owed to cannabis brands and the state in unpaid taxes.&nbsp;
The company laid off the majority of its workforce, leaving only a small team to manage collections from retailers, many of whom were also struggling to pay what they owed. Herbl's receivership underscores the fragility of <a href="https://www.benzinga.com/topic/california-cannabis">California's cannabis infrastructure</a>, where even the largest and seemingly best-established players cannot escape the pressures of overregulation, high taxes and an unpredictable market
Read Also:<a href="https://www.benzinga.com/markets/cannabis/21/11/24264808/co-founder-of-flow-cannabis-calls-for-tax-revolt-in-california-says-regulatory-system-unworkable"> Co-Founder of Flow Cannabis Calls For Tax Revolt In California, Says Regulatory System &#8216;Unworkable&#8217;</a>
<h3 class="wp-block-heading">A Wake-Up Call</h3>
These high-profile failures reveal the volatility of <a href="https://www.benzinga.com/topic/california-cannabis">California's cannabis market</a>. Overregulation, high taxes and competition from illicit operators have strained even the biggest companies. The collapse of MedMen, Eaze, FlowKana and Herbl has left thousands of people jobless, and the cannabis sector grapples with the need for reform to prevent further losses.
Read Next:<a href="https://www.benzinga.com/markets/cannabis/24/10/41236050/californias-largest-cannabis-delivery-service-closes-down-lays-off-500-workers"> California&#8217;s Largest Cannabis Delivery Service Closes Down, Lays Off 500 Workers</a>

Cannabis

News

Entrepreneurship

Financing

Asset Sales

Management

Markets

Epic Cannabis Fails You Should Know About: MedMen, Eaze And Others Go Down In California Meltdowns

Toronto-Dominion Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TD#NYSE">TD</a>) agreed to pay approximately $3.09 billion in fines to U.S. authorities after pleading guilty on Thursday to money laundering-related charges in an <a href="https://www.benzinga.com/government/24/10/41271816/td-bank-to-face-3b-penalty-growth-limits-in-us-settlement-over-anti-money-laundering-failures">ongoing case</a> brought by federal prosecutors, who accused the Canadian bank of essentially making it easy for criminals and cartels to move money around the world for nearly a decade.
"By making its services convenient for criminals, TD Bank became one," said Attorney General Merrick B. Garland on Thursday. "Today, TD Bank also became the largest bank in U.S. history to plead guilty to Bank Secrecy Act program failures, and the first U.S. bank in history to plead guilty to conspiracy to commit money laundering."  
The penalties are the largest ever imposed by U.S. authorities on a bank for money laundering violations.
Read Also: <a href="https://www.benzinga.com/government/24/10/41271816/td-bank-to-face-3b-penalty-growth-limits-in-us-settlement-over-anti-money-laundering-failures">TD Bank To Face $3B Penalty, Growth Limits In US Settlement Over Anti-Money Laundering Failures</a>
Referring to court documents from between January 2014 and October 2023, the Justice Department's Office of Public Affairs <a href="https://www.justice.gov/opa/pr/td-bank-pleads-guilty-bank-secrecy-act-and-money-laundering-conspiracy-violations-18b">stated, </a>"TD Bank had long-term, pervasive, and systemic deficiencies in its U.S. AML policies, procedures and controls but failed to take appropriate remedial action."
<h1 class="wp-block-heading">Employees Involved?</h1>
Federal prosecutors also said some of the bank's employees had enabled the money laundering the bank was slow to detect and address.
"TD Bank's persistent prioritization of growth over controls allowed its employees to break the law and facilitate the laundering of hundreds of millions of dollars," stated Michael J. Hsu, the acting Comptroller of the Currency, <a href="https://www.nytimes.com/2024/10/10/business/td-bank-fine.html">reported</a> the New York Times.
<h1 class="wp-block-heading">Rare But Stern Response: Asset Cap</h1>
The Office of the Comptroller imposed an asset cap that will prevent TD Bank from growing beyond its current $370 billion in assets and curbing its growth in a key market. This marks the first such restriction on a major bank since Wells Fargo in 2018. &nbsp;
"The imposition of an asset cap will ensure that the bank focuses on building proper controls commensurate with its risk profile," Hsu said.
The TD Bank Group, Canada's second-largest bank, has over 1,000 branches in the U.S.&nbsp;
"The bank is also pleading guilty to criminal charges brought by law enforcement authorities," <a href="https://www.federalreserve.gov/newsevents/pressreleases/enforcement20241010a.htm">noted</a> the Federal Reserve in a press release. "The Board&#8217;s action will help ensure that TD operates in compliance with all U.S. laws and regulations."
Read Now:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41250936/this-wells-fargo-analyst-turns-bullish-here-are-top-5-upgrades-for-tuesday">This Chewy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday</a></li>
</ul>
TD Price action: TD Bank stock closed Thursday 5.29% lower at $59.44 per share at market close on Thursday.
Photo: JHVE Photo via Shutterstock

Government

Large Cap

Legal

Global

General

TD Bank Pays $3B Fine After Pleading Guilty In Money Laundering Case, 'Making Its Services Convenient For Criminals'

A Major League Baseball team is up for sale and while billionaire Warren Buffett likely isn't buying the team, he could benefit thanks to a small stake<a href="https://www.benzinga.com/general/sports/23/11/35837148/warren-buffett-finds-sweet-spot-hits-home-run-with-stake-in-major-league-baseball-team"> in another team.</a>
What Happened: The sale of <a href="https://www.benzinga.com/topic/mlb">Major League Baseball </a>(MLB) teams has been rare in recent years, which means a new sale could reset the valuation metrics of teams, an item that shareholders of Atlanta Braves Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BATRA#NASDAQ">BATRA</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BATRK#NASDAQ">BATRK</a>) will be watching.
The Pohlad Family, which has owned the Minnesota Twins since 1984, announced Thursday that the team is up for sale.
Carl Pohlad, who passed away in 2009, bought the Twins for $44 million in 1984, as reported by <a href="https://www.sportico.com/business/team-sales/2024/minnesota-twins-for-sale-pohlad-family-1234800592/">Sportico</a>. His children Jim, Bob and Bill inherited the team upon his death. Jim Pohlad currently serves as the team's controlling owner.
"After months of thoughtful consideration, our family reached a decision this summer to explore selling the Twins. As we enter the next phase of this process, the time is right to make this decision public," the team said.
The Twins won World Series titles in 1987 and 1991 as the Twins and the franchise previously won a title as the Washington Senators in 1924, prior to moving to Minnesota in 1961.
The team has made the MLB Playoffs in four of the past 10 years, winning only one playoff series over the same time period.
The Twins narrowly missed making the playoffs in 2024 with an 82-80 record. General Manager Thad Levine announced he was leaving after eight years with the team. Manager Rocco Baldelli is slated to return for a seventh season in 2025. One plus for the Twins is having managerial stability with only four managers over the last 38 years.
A negative for the team and a potential new owner will be trying to improve television revenue. A deal with Bally Sports North expired after the 2023 season and Diamond Sports Group paid a reduced rate to have Twins games in 2024. The league announced they will take over production and distribution of Twins games and negotiate future deals.
You may not be a billionaire like Warren Buffett, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/general/entertainment/24/10/41187322/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: Ownership of baseball teams like many professional sports teams is often reserved for the wealthiest people.
Baseball has a history of corporations owning teams, a rule that it no longer allows other than the Toronto Blue Jays, owned by Rogers Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCI#NYSE">RCI</a>), who are grandfathered in.
Previously, other MLB teams had corporate owners, which included:
<ul>
<li>St. Louis Cardinals: Anheuser-Busch</li>
<li>Chicago Cubs: Tribune Company</li>
<li>New York Yankees: CBS</li>
<li>Seattle Mariners: Nintendo</li>
<li>Los Angeles Angels: Disney</li>
</ul>
Private equity companies can own minority stakes in MLB teams but can't own a team outright. MLB has allowed private equity investments for years, while the NFL is just now<a href="https://www.benzinga.com/general/sports/24/08/40607642/jeff-bezos-could-have-competition-if-he-wants-the-nfls-seattle-seahawks-private-equity-investments"> coming around to the practice</a> to help improve investment opportunities for team owners.
The Twins are valued at $1.7 billion by <a href="https://www.sportico.com/feature/mlb-team-values-rankings-list-1234715821/">Sportico</a>, ranking 19th of 30 MLB teams. Here are the most recent MLB team sales:
<ul>
<li>2024: Baltimore Orioles, $1.725 billion</li>
<li>2020: New York Mets, $2.42 billion</li>
<li>2019: Kansas City Royals, $1 billion</li>
<li>2017: Miami Marlins, $1.2 billion</li>
<li>2016: Seattle Mariners, $1.4 billion</li>
<li>2012: Los Angeles Dodgers, $2.15 billion</li>
</ul>
The Washington Nationals and Los Angeles Angels hired bankers for potential sales but did not end up selling the teams.
The low number of recent sales could put the Twins in demand with sports ownership often viewed as a strong investment opportunity.
This could be great news for the Atlanta Braves, which are valued at $3.4 billion, ranking sixth by Sportico.
The Braves holding company, which is publicly traded, has a market capitalization of $2.5 billion and enterprise value of $3.1 billion. While the team already trades under the Sportico valuation, the sale of the Twins at a premium to the valuation, it could see other MLB teams rise in the rankings.
Buffett owns a small stake (233,645 shares) in the publicly traded Braves via Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) and has a love for the game of baseball. The billionaire previously owned a stake in a minor league baseball team and had interest in buying the Chicago Cubs.
BATRA Price Action: Atlanta Braves Holdings stock closed Thursday at $41.57 versus a 52-week trading range of $36.78 to $46.65. The stock is down 1.1% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/sports-betting/24/04/38022637/atlanta-braves-stock-could-be-undervalued-based-on-mlb-team-valuations-did-warren-buffett-">Atlanta Braves Stock Could Be Undervalued Based On MLB Team Valuations, Did Warren Buffett Spot Another Value Stock?</a></li>
</ul>
Photos: Shutterstock

Sports

Trading Ideas

BATRA

BATRK

Warren Buffett Home Run? Billionaire's Baseball Bet Could Rise In Value With Minnesota Twins Sale

Sacramento is exploring the possibility of allowing on-site cannabis consumption at dispensaries through a new pilot program. 
If approved, this <a href="https://sacramento.granicus.com/MetaViewer.php?view_id=25&amp;clip_id=6047&amp;meta_id=795533">pilot program</a> would introduce consumption lounges, giving residents a safe and social space to enjoy cannabis legally in the capital city of California.
<h3 class="wp-block-heading">Consumption Lounge</h3>
The proposal, led by Councilmember Katie Valenzuela, would allow two types of cannabis lounges. 
The first would focus on the sale and consumption of cannabis-infused edibles and drinks, providing a more discreet option for those looking to avoid smoking.
The second would permit smoking on site with strict safety measures in place. Valenzuela has championed this initiative for two years, contending it would create a controlled environment for cannabis users to learn and engage with the product safely. "If you have kids at home, you can keep it completely away from them. It never comes into the house," she said in an <a href="https://www.abc10.com/article/news/local/sacramento-cannabis-lounges/103-cab4aee7-b84f-412b-a5c7-869e3b6c693d">interview</a> with ABC10.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Positive Signs From Previous Trials</h3>
Sacramento has already tested the concept of on-site consumption at the <a href="https://www.benzinga.com/markets/cannabis/24/07/39782466/californias-first-cannabis-friendly-state-fair-with-on-site-sales-and-consumption">State Fair </a>earlier this year.
The event allowed cannabis users to consume in a designated area, providing a glimpse of what future consumption lounges could look like.
Valenzuela says these lounges could position Sacramento as a leader in cannabis culture in the region.
"There were dozens and dozens of people there from all walks of life mingling and hanging&#8230;I could just get a picture of what this experience looked like," she said.
Maisha Bahati, CEO of Crystal Nugs, is among those preparing for the potential legalization of on-site consumption. Her dispensary already has a dedicated space for social events, from live music to game nights, once the lounges are approved. "You're going to be around like-minded people…just a normal place where people can come and can consume cannabis," she <a href="https://www.abc10.com/article/news/local/sacramento-cannabis-lounges/103-cab4aee7-b84f-412b-a5c7-869e3b6c693d">told</a> ABC10.
Two more hearings will take place before the proposal moves forward. A final vote is expected by the end of October.
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/41012794/gov-newsoms-hemp-ban-goes-into-effect-consequences-for-industry-investors-patients">Gov. Newsom&#8217;s Hemp Ban Goes Into Effect: Consequences For Industry, Investors, Patients</a>
<h3 class="wp-block-heading">Shifting Califonia Cannabis Landscape</h3>
California's recent&nbsp;initiatives regarding cannabis include <a href="https://www.benzinga.com/markets/cannabis/24/08/40666298/will-california-embrace-cannabis-farmers-markets-and-pot-cafes-gov-newsoms-crucial-decision-ahea">farmer&#8217;s markets</a> and <a>Amsterdam-style&nbsp;cannabis&nbsp;cafes</a>. These proposals aim to alleviate the challenges facing the state&#8217;s cannabis industry.
High taxes, low prices and competition from unlicensed markets have pressured legal businesses into a downturn. In response, lawmakers are exploring solutions to stabilize the sector. Allowing small growers to sell directly and creating social consumption spaces are two possible steps.
Meanwhile, some companies have been <a href="https://www.benzinga.com/markets/cannabis/24/08/40465710/why-are-so-many-california-cannabis-companies-switching-to-hemp-products">shifting to hemp</a> to avoid heavy regulatory burdens. However, Governor Gavin Newsom recently <a href="https://www.benzinga.com/markets/cannabis/24/09/41012794/gov-newsoms-hemp-ban-goes-into-effect-consequences-for-industry-investors-patients">ruled out </a>most hemp products and manufacturing in the state after imposing an emergency ban for which he is facing <a href="https://www.benzinga.com/markets/cannabis/24/09/40756333/gov-newsom-proposes-emergency-rules-to-severely-restrict-hemp-products-this-will-destroy-our-bus">legal resistance</a> from industry stakeholders.
<ul>
<li>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40819034/gov-newsom-is-mulling-over-whether-to-approve-amsterdam-style-cannabis-cafes-in-california">Gov. Newsom Is Mulling Over Whether To Approve Amsterdam-Style Cannabis Cafes In California</a></li>
</ul>

Regulations

Unwinding Among Friends In A Cannabis Lounge Could Soon Be Reality In Sacramento

AMLI

American Lithium Says Taken Proactive Steps, Including Cost-cutting Measures,  To Adapt To Evolving Market Conditions

PROC

Procaps Group Says Independent Investigation Has Identified Certain Historical Transactions, To Restate Financial Statements, Plans Long-term Restructuring Plan

Vertiv Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) has outperformed the market over the past 5 years by 46.06% on an annualized basis producing an average annual return of 60.09%. Currently, Vertiv Hldgs has a market capitalization of $40.30 billion. 
Buying $100 In VRT: If an investor had bought $100 of VRT stock 5 years ago, it would be worth $1,050.54 today based on a price of $107.43 for VRT at the time of writing.
<h3>Vertiv Hldgs's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728595824_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth $1,100 Today

L3Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) has outperformed the market over the past 15 years by 1.04% on an annualized basis producing an average annual return of 12.78%. Currently, L3Harris Technologies has a market capitalization of $45.98 billion. 
Buying $1000 In LHX: If an investor had bought $1000 of LHX stock 15 years ago, it would be worth $6,511.28 today based on a price of $242.35 for LHX at the time of writing.
<h3>L3Harris Technologies's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728595820_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth $6,500 Today

Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) shares traded lower Thursday as the company hosted its <a href="https://www.benzinga.com/pressreleases/24/10/g41278525/amd-unveils-leadership-ai-solutions-at-advancing-ai-2024">"Advancing AI 2024" event.&nbsp;</a>
The Details: AMD launched several new high-performance computing solutions at the event, including fifth Gen AMD EPYC server CPUs, AMD Instinct MI325X accelerators, AMD Pensando Salina DPUs, AMD Pensando Pollara 400 NICs and AMD Ryzen AI PRO 300 series processors for enterprise AI PCs.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/24/10/41277250/whats-going-on-with-first-solar-stock">What&#8217;s Going On With First Solar Stock?</a>
&#8220;The data center and AI represent significant growth opportunities for AMD, and we are building strong momentum for our EPYC and AMD Instinct processors across a growing set of customers,&#8221; said AMD Chair and CEO Dr. Lisa Su.&nbsp;
&#8220;With our new EPYC CPUs, AMD Instinct GPUs and Pensando DPUs we are delivering leadership compute to power our customers&#8217; most important and demanding workloads. Looking ahead, we see the data center AI accelerator market growing to $500 billion by 2028," added Su.&nbsp;
Several partners, including Dell, Google Cloud, HPE, Meta, Microsoft and Super Micro, showcased how they deploy AMD's AI solutions at scale. Microsoft CEO Satya Nadella pointed to the company's long-standing collaboration with AMD across its product offerings and Google highlighted how AMD EPYC processors power a wide range of instances for AI, high performance and general purpose and confidential computing. 
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, AMD shares moved on heavy volume during Thursday's event and are trading above the stock's 50-day moving average of $149.92.&nbsp;
<h1 class="wp-block-heading">Will AMD Stock Go Up?</h1>
When trying to assess whether or not Advanced Micro Devices will trade higher from current levels, it's a good idea to take a look at analyst forecasts. 
Wall Street analysts have an average 12-month price target of $191.19 on Advanced Micro Devices. The Street high target is currently at $250 and the Street low target is $156. Of all the analysts covering Advanced Micro Devices, 14 have positive ratings, two have neutral ratings and no one has a negative rating.
In the last month, three analysts have adjusted price targets. Here's a look at recent price target changes <a href="https://www.benzinga.com/quote/AMD/analyst-ratings">[Analyst Ratings]</a>. Benzinga also tracks Wall Street's most accurate analysts. Check out how analysts covering Advanced Micro Devices have performed in recent history.
Stocks don't move in a straight line. The average stock market return is approximately 10% per year. Advanced Micro Devices is 18.47% up year-to-date. The average analyst price target suggests the stock could have further upside ahead.
For a broad overview of everything you need to know about Advanced Micro Devices, visit <a href="https://www.benzinga.com/quote/AMD">here</a>. If you want to go above and beyond, there's no better tool to help you do just that than <a href="https://pro.benzinga.com/">Benzinga Pro</a>. Start your free trial today.
AMD Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, AMD shares ended Thursday's session 4% lower at $164.18.&nbsp;
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41261919/what-happened-with-celsius-holdings-stock-today">What Happened With Celsius Holdings Stock Today?</a></li>
</ul>
Photo: Shutterstock&nbsp;

Movers

Tech

What Happened With AMD Stock Today?

RIV Capital Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/RIV#CSE">RIV</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>) and Cansortium Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/TIUM#CSE">TIUM</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTCQB">CNTMF</a>) have secured approval from the New York Cannabis Control Board for their upcoming merger, marking a major consolidation in the state's fast-growing cannabis industry. 
The merger, expected to close by the end of 2024, positions the combined company to take full advantage of<a href="https://www.benzinga.com/markets/cannabis/24/05/39094250/this-cannabis-merger-will-cover-25-of-u-s-population-cansortium-riv-capital-powered-by-scottsmir"> covering 25% of the U.S. population</a> with eight cultivation and processing facilities and 42 retail dispensaries.
&#8220;We are thrilled to have received regulatory approval in New York to move forward with our business combination transaction, bringing us closer to completing this important step for both of our companies in the fourth quarter of 2024,&#8221; said Robert Beasley, CEO of Cansortium, in a press release Thursday afternoon.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h3 class="wp-block-heading">New York's Cannabis Boom</h3>
With adult-use cannabis sales now in full swing, New York has quickly become a battleground for companies looking to expand their market share. RIV Capital, which operates three retail locations in the state, has seen rapid growth in both its consumer-facing and wholesale businesses since adult-use sales began earlier this year.
Cansortium, a vertically integrated company operating under the FLUENT&#x2122; brand, brings significant expertise from other key markets, including<a href="https://www.benzinga.com/topic/florida-cannabis"> Florida</a>, Pennsylvania, and<a href="https://www.benzinga.com/topic/texas-cannabis"> Texas</a>. 
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/10/41277104/exclusive-80-growth-despite-the-chaos-how-dutchie-c3-defy-2024s-cannabis-slump"> EXCLUSIVE: 80% Growth Despite The Chaos: How Dutchie, C3 Defy 2024&#8217;s Cannabis Slump</a>
<h3 class="wp-block-heading">What This Means For Investors</h3>
For cannabis investors, this <a href="https://www.newswire.ca/news-releases/riv-capital-and-cansortium-receive-new-york-state-cannabis-control-board-approval-for-change-of-control-851372999.html">merger</a> signals a unique opportunity to gain exposure to a rapidly expanding market. RIV Capital's partnership with The Hawthorne Collective, a subsidiary of ScottsMiracle-Gro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>), further strengthens its position in the cannabis supply chain. Meanwhile, Cansortium's operational expertise in cultivation, production and retail will likely drive significant value for shareholders.
<h3 class="wp-block-heading">Closing Timeline And Further Details</h3>
<ul>
<li>The merger between RIV Capital and Cansortium is expected to close by the fourth quarter of 2024, pending final closing conditions. </li>
<li>Upon completion, Cansortium&#8217;s shares will continue trading on the Canadian Securities Exchange under the symbol &#8216;TIUM.U&#8217; and on the OTCQB Venture Market under &#8216;CNTMF.&#8217; </li>
<li>Further details, including the principal closing conditions, can be found in RIV Capital&#8217;s management information circular dated July 12, 2024.</li>
</ul>
Read Next:<a href="https://www.benzinga.com/markets/cannabis/24/10/41273594/tilray-reports-200m-q1-net-revenue-up-13-yoy-as-net-loss-improves"> Tilray Reports $200M Q1 Net Revenue, Up 13% YoY As Net Loss Improves</a>

Contracts

CNPOF

CNTMF

CSE:RIV

CSE:TIUM

Major Cannabis Merger Approved In New York: Can Weed Stock Investors Take Advantage?

The dividend will be paid on Nov. 15, 2024 to shareholders of record on Oct. 31, 2024. The Company&#39;s indicated annual dividend rate is&nbsp;$1.96&nbsp;per share.

Dividends

Northwest Natural Holding Increases Quarterly Dividend From $0.4875 To $0.49 Per Share

Jet.AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTAI#NASDAQ">JTAI</a>) shares fell Thursday after the company announced it entered into an agreement with certain institutional investors to purchase approximately 26.6 million shares of common stock in a <a href="https://www.benzinga.com/pressreleases/24/10/g41279369/jet-ai-announces-pricing-of-2-4-million-registered-direct-offering">registered direct offering. </a>
The Details: Jet.AI announced the pricing of the offering will be nine cents per share with gross proceeds of approximately $2.4 million to the company before deducting the estimated offering expenses. The offering is expected to close on or about Oct. 11. 
Read Next: <a href="https://www.benzinga.com/fintech/24/10/41234302/whats-going-on-with-sofi-stock">What&#8217;s Going On With SoFi Stock?</a>
Jet.AI shares reached an intraday high of 25 cents before reversing in afternoon trading when the direct offering was announced. The stock moved lower on heavy trading volume with more than 805 million shares traded in Thursday's session, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>. 
<h1 class="wp-block-heading">How To Buy JTAI Stock</h1>
Besides going to a brokerage platform to purchase a share — or fractional share — of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Jet AI's case, it is in the Industrials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
JTAI Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Jet.AI shares are up 8.57% after-hours at 8 cents after falling 11.77% in regular trading Thursday.  
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41261919/what-happened-with-celsius-holdings-stock-today">What Happened With Celsius Holdings Stock Today?</a></li>
</ul>
Image: Shutterstock

Penny Stocks

Offerings

After-Hours Center

JTAI

What Happened With Jet.AI Stock Today?

The&nbsp;dividend is payable on&nbsp;November 27, 2024&nbsp;to shareholders of record at the close of business on&nbsp;November 13, 2024.

MSC Industrial Supply Boosts Quarterly Cash Dividend From $0.83 To $0.85 Per Share

6 analysts have shared their evaluations of Assurant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $214.17, along with a high estimate of $233.00 and a low estimate of $194.00. Surpassing the previous average price target of $206.83, the current average has increased by 3.55%.
<img src="https://www.benzinga.com/files/images/story/2024/1728594098_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Assurant among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grace Carter</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$233.00</td>
<td>$228.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$217.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>John Nadel</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$224.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Tommy McJoynt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$194.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>John Nadel</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$217.00</td>
<td>$210.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Assurant. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Assurant compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Assurant's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Assurant's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/AIZ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Assurant analyst ratings.</a>
<h2>All You Need to Know About Assurant</h2>
Assurant Inc offers a range of property-casualty, health, employee benefit, and warranty insurance to a client base made up of individuals and institutions. Its segments are Global Housing, Global lifestyle, Corporate and Other. Global Housing provides lender-placed homeowners insurance, lender-placed manufactured housing insurance and lender-placed flood insurance; renters insurance and related products; and voluntary manufactured housing insurance, voluntary homeowners insurance and other specialty products. Global Lifestyle, the key revenue-generating segment, provides mobile device solutions and extended service products and related services for mobile devices, consumer electronics and appliances; vehicle protection; and credit protection and other insurance products.
<h3>Assurant: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Assurant's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 7.08%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Assurant's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 6.45%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Assurant's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.8%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Assurant's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.56%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.42, caution is advised due to increased financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

6 Analysts Have This To Say About Assurant

Across the recent three months, 4 analysts have shared their insights on Climb Global Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMB#NASDAQ">CLMB</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $84.5, a high estimate of $90.00, and a low estimate of $68.00. Observing a 6.96% increase, the current average has risen from the previous average price target of $79.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1728594088_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive Climb Global Solutions is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vincent Colicchio</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Vincent Colicchio</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Vincent Colicchio</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Vincent Colicchio</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Climb Global Solutions. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Climb Global Solutions compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Climb Global Solutions's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Climb Global Solutions's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CLMB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Climb Global Solutions analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Climb Global Solutions: A Closer Look</h2>
Climb Global Solutions Inc is a cloud-based, value-added IT distribution and solutions company specializing in emerging technologies. It operates across the USA, Canada, and Europe through multiple business units, including Climb Channel Solutions, Sigma, Grey Matter, Interwork, and TechXtend. The Company is organized into two reportable operating segments. The Distribution segment distributes technical software to corporate resellers, value-added resellers (VARs), consultants, and systems integrators under the name Climb Channel Solutions. The Solutions segment is a cloud solutions provider and value-added reseller of software, hardware, and services to customers under the name Grey Matter.
<h3>A Deep Dive into Climb Global Solutions's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Climb Global Solutions's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 12.66% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: Climb Global Solutions's net margin is impressive, surpassing industry averages. With a net margin of 3.63%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Climb Global Solutions's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.28%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.11%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.03, Climb Global Solutions adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLMB

Breaking Down Climb Global Solutions: 4 Analysts Share Their Views

Ratings for Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) were provided by 19 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Biogen and provided 12-month price targets. The average target is $262.63, accompanied by a high estimate of $302.00 and a low estimate of $190.00. A decline of 3.85% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1728594071_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Biogen among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$269.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$202.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$292.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Eric Schmidt</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$292.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$251.00</td>
<td>$277.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$302.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$285.00</td>
<td>$288.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$292.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$225.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$244.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$190.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$288.00</td>
<td>$288.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$294.00</td>
<td>$316.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$294.00</td>
<td>$294.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biogen. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Biogen compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Biogen's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Biogen's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BIIB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Biogen analyst ratings.</a>
<h2>About Biogen</h2>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
<h3>A Deep Dive into Biogen's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Biogen showcased positive performance, achieving a revenue growth rate of 0.36% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Biogen's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 23.68%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Biogen's ROE stands out, surpassing industry averages. With an impressive ROE of 3.75%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Biogen's ROA excels beyond industry benchmarks, reaching 2.19%. This signifies efficient management of assets and strong financial health.
Debt Management: Biogen's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.42.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIIB

The Latest Analyst Ratings For Biogen

This new authorization replaces all previous authorizations. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.
The Board also declared a quarterly cash dividend of&nbsp;$0.45&nbsp;per share. The payment date is November 14, 2024, to stockholders of record as of October 24, 2024.

Buybacks

AptarGroup Plans Repurchase Of Up To $500M Of Common Stock

W.P. Carey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPC#NYSE">WPC</a>) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for W.P. Carey, presenting an average target of $61.88, a high estimate of $66.00, and a low estimate of $56.00. Marking an increase of 2.93%, the current average surpasses the previous average price target of $60.12. 
<img src="https://www.benzinga.com/files/images/story/2024/1728594053_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of W.P. Carey among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brendan Lynch</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$56.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Conor Siversky</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$63.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$66.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$63.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>James Feldman</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$62.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$60.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Michael Goldsmith</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$63.00</td>
<td>$57.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to W.P. Carey. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of W.P. Carey compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for W.P. Carey's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of W.P. Carey's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/WPC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on W.P. Carey analyst ratings.</a>
<h2>Delving into W.P. Carey's Background</h2>
W.P. Carey Inc is a real estate investment trust principally involved in the ownership of properties located in the U.S., Western Europe, and Northern Europe. W.P. Carey organizes its operations into Real Estate and Investment Management segments. The vast majority of the company's income is derived from its Real Estate division in the form of lease revenue from long-term agreements with companies. W.P. Carey's real estate portfolio is primarily comprised of single-tenant office, industrial, warehouse, and retail facilities located around the world. most of the company's revenue comes from properties in the USA. The company's Investment Management unit generates revenue from providing real estate advisory and portfolio management services to other REITs.
<h3>W.P. Carey's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Challenges: W.P. Carey's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -13.9%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: W.P. Carey's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 36.67% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): W.P. Carey's ROE stands out, surpassing industry averages. With an impressive ROE of 1.65%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.81%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.94, W.P. Carey adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 8 Analyst Ratings For W.P. Carey

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Genenta Science SpA Sponsored ADR (GNTA – Research Report). The associate...

Buy Rating for Genenta Science SpA on Strong Clinical Prospects and Innovative Gene Therapy Platform

Genenta Science SpA Sponsored ADR (GNTA) has disclosed a new risk, in the Share Price & Shareholder Rights category. Genenta Science's proposed loy...

Genenta Science's Loyalty Shares: A Double-Edged Sword for ADS Liquidity and Investor Influence?

Genenta Science SpA Sponsored ADR (GNTA) has released an update. Genenta Science SpA invites its shareholders to the upcoming ordinary and extraord...

Genenta Science Announces Shareholder Meeting

Genenta Science SpA Sponsored ADR (GNTA) has released an update. Genenta Science's CEO Pierluigi Paracchi has proposed a new slate of candidates fo...

Genenta Science Announces Board Restructuring

Genenta Science SpA Sponsored ADR (GNTA) has released an update. Genenta Science SpA, an Italian biotech firm, has entered into an agreement with V...

Genenta Science Announces ADS Sales Agreement

Genenta Science SpA Sponsored ADR (GNTA) has released an update. Genenta Science SpA, a biotech company based in Milan, is focused on the research,...

Genenta Science Advances Biotech Endeavors

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cingulate Inc (CING – Research Report) and Genenta...

Analysts Conflicted on These Healthcare Names: Cingulate Inc (CING) and Genenta Science SpA Sponsored ADR (GNTA)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks.</a> Developing therapeutics to cure diseases is a complex business model fraught with the potential to fail at many points.&nbsp;



Developmental and regulatory time frames are long, introducing multiple potential points of failure. The capital necessary for research and development is substantial. So on and so forth. The result is that many&nbsp;upstart biotech firms fail to commercialize, taking their equity down in the process.



Those firms that make it through and reach commercialization are rewarded with the spoils of success. They pay shareholders handsomely with returns that can turn a small investment into a fortune. The firms discussed below still have reasonable chances of commercialization and the potential to reward investors handsomely. Even if they don&rsquo;t ultimately reach success, they can still reward investors handsomely as they pass milestones in the development process.



<h2>FibroGen (FGEN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div>FibroGen (NASDAQ:<a href="https://investorplace.com/stock-quotes/fgen-stock-quote/">FGEN</a>) continues on the path toward commercialization for multiple drugs, targeting multiple diseases. The firm&rsquo;s leading candidate drugs include Pamrevlumab, Roxadustat and several other oncology therapeutics.



Pamrevlumab is currently in Phase 3 clinical trials for the treatment of a certain form of pancreatic cancer. It is also concurrently being studied in phase 2/3&nbsp;clinical studies for metastatic pancreatic cancer. Roxadustat is a drug that induces the production of red blood cells and is approved in multiple countries for use in treating anemia in chronic kidney disease populations. A supplemental New Drug Application (sNDA) has been submitted in China for the drug. It has been accepted for review by the China Health Authority.&nbsp;



One of the more compelling aspects of FibroGen as an investment in financial performance. During the <a href="https://www.globenewswire.com/news-release/2024/05/06/2876129/33525/en/FibroGen-Reports-First-Quarter-2024-Financial-Results.html">first quarter, revenues</a> approached $56 million, up from $36 million a year earlier. The increased revenues allow the company to slash its net losses from $76.7 million to just below $32 million this quarter. Shares currently trade for $1.30 with a <a href="https://stockanalysis.com/stocks/fgen/forecast/">consensus target price of $5</a> and analyst targets ranging as high as $11.



<h2>Nuvectis Pharma (NVCT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>Nuvectis Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvct-stock-quote/">NVCT</a>) is another oncology-oriented biotech stock. It&rsquo;s particularly interesting as a potential investment because while it is in the pre-revenue stages, it is also highly regarded and priced higher than one might expect.



Shares currently trade for $6.21, which is quite high for a pre-revenue biotech firm. Those shares have coverage from a single analyst who expects their value to rise to $22 in the future. Investors who look at the company&rsquo;s financial statements will see that it is basically treading water. NVCT has more than $19 million in liquidity and loses roughly $4 million a quarter on R&amp;D and administrative costs.&nbsp;



The reason for optimism surrounding Nuvectis Pharma is simple: Lead candidate drug <a href="https://www.globenewswire.com/news-release/2024/05/07/2876700/0/en/Nuvectis-Pharma-Inc-Reports-First-Quarter-2024-Financial-Results-and-Business-Highlights.html">NXP800 has been granted</a> fast-track designation by the FDA in platinum-resistant ARID1a-mutated ovarian cancer. It&rsquo;s currently in Phase 1b studies and has the potential to pass through multiple milestones moving forward that, if successful, will reward investors with strong and immediate returns.



<h2>Relmada Therapeutics (RLMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div>Relmada Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rlmd-stock-quote/">RLMD</a>) is one of many promising late-stage biotech firms developing therapeutics to address diseases of the central nervous system. Those diseases include disorders with high unmet needs including major depressive disorder (MDD), a primary focus of the firm.



REL-1017 is one of the company&rsquo;s lead candidate drugs. The drug is in late-stage development for the treatment of MDD. It is being studied to understand the potential of the drug as a fast-acting, once-daily antidepressant treatment.&nbsp;It is currently being studied in two Phase 3 double placebo-controlled studies.



The company also acquired the rights to a psilocybin and derivatives program&nbsp;in 2021. That program has been rebranded as REL-P11 and is being studied for its efficacy in both neurogenesis and in ameliorating the effects of neurodegenerative conditions.&nbsp;



Psilocybin and other psychoactive drugs are currently a hot area of research. Although Ralmada Therapeutics is in the pre-revenue stages and shares trade for $3.04, the sole analyst with coverage believes those shares could be worth as much as $25 in the future.



<h2>Anixa Biosciences (ANIX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-1-300x169.jpg" alt="A scientist holds a test tube while it is in a container"><div>Source: Shutterstock</div></div>Anixa Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/anix-stock-quote/">ANIX</a>) develops treatments and vaccines to address unmet needs in ovarian cancer and breast cancer. Shares currently trade for less than $3, while the single analyst with coverage believes the stock will <a href="https://www.pricetargets.com/NASDAQ/ANIX/">rise to $12 in value.</a>&nbsp;



The company very <a href="https://www.prnewswire.com/news-releases/anixa-biosciences-commences-treatment-of-fifth-patient-in-ovarian-cancer-car-t-clinical-trial-302150758.html">recently commenced treatment</a> on the 5th patient in an ovarian cancer CAR-T clinical trial. The company is enrolling patients in its first-in-human trial who were unresponsive to at least two prior therapies. Safety was confirmed in the first three-patient cohort. The company is tripling the dose in patients four and five in order to establish dosage tolerability.&nbsp;



The company also recently expanded its partnership with the Cleveland Clinic to develop cancer vaccines. That partnership aims to further the development of vaccines targeting rare and aggressive forms of breast and ovarian cancer. Anixa Biosciences will continue to be an interesting stock for investors, especially in light of strong positive news on multiple fronts.



<h2>Genenta Science (GNTA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-min-1-300x169.jpg" alt="an image of a microscope, NEXI stock"><div>Source: Shutterstock</div></div>Let&rsquo;s begin discussing Genenta Science (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnta-stock-quote/">GNTA</a>) stock in relation to its safety as an investment overall. Readers have noticed that multiple recommendations above have only one analyst rating. I don&rsquo;t have to explain why that introduces a lot of risk overall. The thing I want to note about Genenta Science is that it has <a href="https://stockanalysis.com/stocks/gnta/forecast/">two target prices,</a> one at $15 and the other at $25. Thus, the consensus price is $20. Genenta Science shares trade at $3.30.



While the company is attractive for its raw return potential, I should also note that there are a lot of unknowns with this company. It is an Italian company and doesn&rsquo;t provide a lot in the way of information. It&rsquo;s a lot easier to find updates on domestic companies. The information we do have is a<a href="https://ir.genenta.com/static-files/db77523d-9bdf-47bd-8120-02eb11e0d7df"> financial report dating from the end of 2023.</a> It simply shows the company is not producing much in the way of revenues.



The stock offers so much potential because the company is developing a stem cell platform for the safe treatment of solid tumors. It has <a href="https://www.globenewswire.com/news-release/2024/02/08/2825783/0/en/Genenta-Demonstrated-Reprogramming-of-the-Tumor-Microenvironment-in-GBM-Patients-Paving-the-Way-for-Innovative-Treatments-of-Solid-Tumors.html">demonstrated the potential</a> to reprogram the cells of glioblastoma patients.&nbsp;



<h2>Affimed (AFMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/red-blood-cells-300x169.jpg" alt="3d rendering red blood cells in vein"><div>Source: Phonlamai Photo / Shutterstock.com</div></div>Affimed (NASDAQ:<a href="https://investorplace.com/stock-quotes/afmd-stock-quote/">AFMD</a>) continues to develop therapeutics for the treatment of lymphoma, a grouping of blood cancers that originate in the lymphatic system.



The stock is interesting for a number of reasons both operational and developmental. The company reduced <a href="https://www.globenewswire.com/news-release/2024/03/28/2853795/0/en/Affimed-Reports-2023-Financial-Results-and-Operational-Progress.html">its workforce by 50% in 2023</a> in an effort to streamline operations.



AFMD is redirecting its resources to three lead candidate programs following the restructuring. That leads me to my next point: The company is doing well from a developmental perspective. Each of those three candidate programs progressed in 2023. Affimed awaits further data readouts from those programs in Q2 and expects dose escalation. That implies current safety and will be used to establish the upper tolerability for those respective programs.&nbsp;



As with any penny biotech stock, failure is a distinct possibility. However, Affimed is well regarded and benefits from a <a href="https://stockanalysis.com/stocks/afmd/forecast/">consensus target price of $32.</a> It currently trades for just over $4.&nbsp;



<h2>Lipocine (LPCN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div>Lipocine (NASDAQ:<a href="https://investorplace.com/stock-quotes/lpcn-stock-quote/">LPCN</a>) stock trades for $6.89 but is expected to rise to $33. Like so many other stocks on this list, Lipocine only has coverage from one analyst. That introduces risk to what is already a risky biotech stock. However, that&rsquo;s the game investors must be willing to play in the risk-fueled world of pharma stock&nbsp;investing.



As you may have guessed by the firm&rsquo;s name, Lipocine does work in the obesity management space. Candidate drug Lpcn2401 is currently in Phase 2 studies and is showing promise in reducing obesity in patients with at least one co-related morbidity.



However, the company is also developing treatments outside of the weight loss realm. Those programs span disease areas, including postpartum depression, cirrhosis, essential tremors and testosterone replacement therapy.&nbsp;



What&rsquo;s particularly good about the company is that it actually produced positive net income in the most recent quarter. Lipocine <a href="https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-first-quarter-ended-march-31-2024-302140431.html">reported $3.5 million in net income</a> in the first quarter, reversing a $3.9 million net loss 12 months prior.



On <a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a> and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More: <a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash; How to Profit Without Getting Scammed</a>



On the date of publication, Alex Sirois did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"> Publishing Guidelines.</a>
<div>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/05/7-penny-biotech-stocks-to-triple-your-investment/">7 Penny Biotech Stocks to Triple Your Investment</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Penny Biotech Stocks to Triple Your Investment

Maxim Group analyst Jason McCarthy maintained a Buy rating on Genenta Science SpA Sponsored ADR (GNTA – Research Report) yesterday and set a price ...

Buy Rating Affirmed for Genenta Science Amid Promising Developments in Gene Therapy Trials

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Danaher (DHR – Research Report) and Genenta Science SpA Sponsored...

Comments

Genenta Science

Noticias

Últimas noticias sobre Genenta Science (NASDAQ:GNTA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL